Smith & Nephew plc (SNN) is a publicly traded Healthcare sector company. As of July 9, 2026, SNN trades at $29.95 with a market cap of $12.88B and a P/E ratio of 0.00. SNN moved +0.00% today. Year to date, SNN is -8.72%; over the trailing twelve months it is +0.60%. Its 52-week range spans $23.69 to $38.79. Analyst consensus is neutral with an average price target of $32.32. Rallies surfaces SNN's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Smith & Nephew Unveils First German Risk-Based sNPWT Guidelines with 300 ml Exudate Cap: Smith & Nephew published Germany’s first risk-based expert consensus for sNPWT in closed surgical incisions, recommending therapy for patients with obesity, diabetes or prolonged surgery and wounds with up to 300 ml exudate weekly. The guidelines aim to streamline PICO 7 adoption and reduce postoperative complications.
| Metric | Value |
|---|---|
| Price | $29.95 |
| Market Cap | $12.88B |
| P/E Ratio | 0.00 |
| EPS | $0.00 |
| Dividend Yield | 0.48% |
| 52-Week High | $38.79 |
| 52-Week Low | $23.69 |
| Volume | 0 |
| Avg Volume | 0 |
| Revenue (TTM) | $0 |
| Net Income | $0 |
| Gross Margin | 0.00% |
4 analysts cover SNN: 0 strong buy, 0 buy, 4 hold, 0 sell, 0 strong sell. Consensus rating is neutral. Average price target: $32.32.